Skip to main
  1. Stocks
  2. Phreesia Inc
  3. Forecast
PHR

Phreesia Inc (PHR) Stock Forecast & Price Target

Phreesia Inc (PHR) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 27%
Buy 33%
Hold 33%
Sell 7%
Strong Sell 0%

Bulls say

Phreesia is attractive because its integrated patient intake, payments, and engagement platform is deeply embedded in provider workflows, creating switching costs while monetizing a scaled network that serves over 4,400 healthcare providers and ~170M patient visits. In 2Q27, revenue of $129.5M rose 10% year over year, adjusted EBITDA reached $32.9M, and the 25.4% margin improved sharply on restructuring and disciplined expense controls, while cash of $74.6M exceeded debt of $61.2M after $23.5M of principal paydown. The bullish case is further supported by 4,744 provider clients, 6.2% client growth, strong network solutions momentum, and early AccessOne progress that could expand patient payment opportunities and lift growth as management reinvests in the core business.

Bears say

Phreesia is facing a muted growth profile as management held FY27 revenue guidance at $515 million, implying 7% year-over-year growth, yet that still translates into less than 1% organic growth and a reduced subscription revenue forecast from +4% to (4%). The outlook is further pressured by a delayed AccessOne ramp into FY28, conservative assumptions for AHSC additions and payment solutions, and execution risk that could weaken free cash flow and debt repayment capacity in the company’s downside case. Although adjusted EBITDA guidance of $125 million to $135 million was reiterated, heavier hiring for Provider Connect and rising AI costs, combined with competition from Epic and Oracle and potential FDA-related ad spending pressure, support a negative fundamental view.

Phreesia Inc (PHR) has been analyzed by 15 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Phreesia Inc and is not a guaranteed prediction by Public.com or investment advice.

Phreesia Inc (PHR) Analyst Forecast & Price Prediction

Get the latest Phreesia Inc (PHR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Phreesia Inc (PHR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Phreesia Inc (PHR) Forecast

Analysts have given Phreesia Inc (PHR) a Buy based on their latest research and market trends.

According to 15 analysts, Phreesia Inc (PHR) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Phreesia Inc (PHR)


Phreesia Inc (PHR) Analyst Forecast & Price Prediction

Get the latest Phreesia Inc (PHR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Phreesia Inc (PHR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PHR stock data and trends